Steered by the association of HER2 and PD-L1 axis in BC dynamics, several new drugs and drug combinations (PD-1/PD-L1 and HER2-targeted) are under clinical investigation for the treatment of HER2+ BC. This evidence concerns the gene CD274 and breast cancer.